South Africa

5.

Kenya successfully procures health commodities without using Global Fund’s pooled procurement

5 Sep 2018
Medical supplies authority obtains competitive prices that are often lower than international averages

The Kenya Medical Supplies Authority (KEMSA) successfully procures and distributes government, Global Fund, and other donor-funded commodities. Prices obtained by KEMSA are competitive compared to prices obtained by the Global Fund’s Pooled Procurement Mechanism (PPM), stock-outs of health commodities occur rarely, if ever, commodities are delivered in a timely fashion, and inventory is properly managed at all stages of the supply chain.

4.

OIG investigation reveals deficiencies in Global Fund processes for procurement of HIV rapid test kits in eight countries

3 Sep 2018
Country teams have already taken corrective action

A proactive investigation undertaken by the Office of the Inspector General (OIG) has identified some deficiencies in the Global Fund’s processes for procuring HIV rapid diagnostic test (RDT) kits. A report on the investigation was released on 31 May 2018.

4.

The Global Fund explores the use of impact bonds and social success notes

21 Aug 2018
Outcomes-based financing approach could reduce the risks associated with innovation
Part 2 of a 3-part series

In the beginning, there was performance-based funding. It was the outcomes-based mechanism of choice for the Global Fund and forms the foundation on which the Global Fund’s grant architecture was built. The idea was simple. Release funding in tranches, whereby recipients were required to reach specific targets before the rest of the grant would be disbursed.

3.

Global Fund to benefit from “breakthrough” ARV pricing agreement

3 Oct 2017
State-of-the-art fixed dose combination regimen will cost $75 per patient per year

In what has been hailed as a “breakthrough” and a “game changer,” a pricing agreement between the Bill and Melinda Gates Foundation and two generic drug companies will result in significant savings in the cost of antiretrovirals (ARVs). As a result of the agreement, starting in 2018 a state-of-the-art fixed dose combination ARV regimen will be available in 92 developing nations at a maximum cost of $75 per patient per year.

3.

Significant improvement needed in Global Fund grants to South Africa, OIG finds

8 Aug 2017
Start-up delays and coordination challenges have hampered implementation

On 19 July 2017, the Global Fund published an audit report by the Office of the Inspector General (OIG) on grants to the Republic of South Africa. The country is part of the Fund’s High Impact Africa 1 portfolio and has $312 million in signed grants for the implementation period April 2016 to March 2019.

3.

Global Fund pushes back on claims of overdependence on select suppliers of ARVs

17 Apr 2017
Buyers had been warned to diversify the manufacturing base or risk supply interruptions

The Global Fund, one of the main purchasers of generic antiretroviral (ARV) medicines for HIV patients in low- and middle-income countries, has dismissed concerns that the limited number of manufacturers tapped to supply these drugs could result in immediate or future shortages. Fund officials said systems are in place to forecast demand, deal with any supply disruptions and increase production to meet future need.

6.

Is South Africa transitioning?

3 Oct 2016
Changing Global Fund priorities and a new NSP prompt discussions on sustainability

In a recent ICASO discussion paper called “Handing over Health”, a review of sustainability and transition literature is complemented by country case studies from Serbia, Thailand and South Africa.

8.

New regional grant has sights set on malaria elimination in Southern Africa

5 Oct 2015

Elimination 8 (E8) has set the formidable target of full malaria elimination in Botswana, Namibia, South Africa and Swaziland by 2020. Termed the “frontline four”, these countries are nearing elimination of the disease after achieving a 75% decline between 2000 and 2012.

6.

South Africa submits $380-million concept note for HIV/TB

17 Jul 2015
Emphasis on prevention could make Global Fund single largest investor in targeted programming for key populations

South Africa on 15 July submitted a joint HIV/TB concept note for some $380.5 million in funding, more than half of which is to support prevention interventions specifically targeting key populations including young women and girls, men who have sex with men and people living in disease hot spots. Of this, $142.2 million constitutes an above-allocation request.

3.

New funding model brings promising change as African countries request millions for key populations

27 Jan 2015

There is mounting evidence that within southern Africa’s generalized HIV epidemic there are under-estimated concentrated epidemics among key affected populations (KAPs) such as sex workers and men who have sex with men (MSM).

Pages

Subscribe to South Africa